We serve Chemical Name:2,4-Dichloro-6-Morpholino-1,3,5-Triazine CAS:6601-22-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2,4-Dichloro-6-Morpholino-1,3,5-Triazine
CAS.NO:6601-22-5
Synonyms:4,6-dichloro-N-morpholinyl-1,3,5-triazine-2-amine;2,4-dichloro-6-morpholino-s-triazine;2,4-dichloro-6-morpholin-4-yl-1,3,5-triazine;2,4-Dichloro-6-(4-morpholinyl)-1,3,5-triazine;2,4-Dichloro-6-(morpholin-4-yl)-1,3,5-triazine;2,4-Dichloro-6-morpholin-4-yl-[1,3,5]triazine;2,4-dichloro-6-morpholino-4-yl-1,3,5-triazine;Morpholine, 4-(4,6-dichloro-1,3,5-triazin-2-yl)-;2,4-dichlor-6-(morpholin-4-yl)-1,3,5-triazin;2,4-Dichloro-6-Morpholino-1,3,5-Triazine
Molecular Formula:C7H8Cl2N4O
Molecular Weight:235.071
HS Code:2934999090
Physical and Chemical Properties:
Melting point:137ºC
Boiling point:441.9±55.0 °C at 760 mmHg
Density:1.5±0.1 g/cm3
Index of Refraction:1.581
PSA:51.14000
Exact Mass:234.007523
LogP:0.56
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4,6-dichloro-N-morpholinyl-1,3,5-triazine-2-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,4-Dichloro-6-Morpholino-1,3,5-Triazine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,4-dichloro-6-morpholino-s-triazine Use and application,2,4-Dichloro-6-(4-morpholinyl)-1,3,5-triazine technical grade,usp/ep/jp grade.
Related News: Australia has started denying entry to all travelers who have come from or transited through mainland China. 2,4-Dichloro-6-Morpholino-1,3,5-Triazine manufacturer Australia has started denying entry to all travelers who have come from or transited through mainland China. 2,4-Dichloro-6-Morpholino-1,3,5-Triazine supplier The U.S. Food & Drug Administration on Friday said Johnson & Johnson (JNJ.N) must throw away millions of doses of its COVID-19 vaccine that were manufactured at a problem-plagued Baltimore factory but also cleared millions for use. 2,4-Dichloro-6-Morpholino-1,3,5-Triazine vendor But even though weight-loss success depends on adopting a challenging” change in post-operation diet and lifestyle, the process can certainly “help people to lose weight and get comorbid [other negative health] conditions under better control,” Sandon said.
So it’s important, she said, to help eligible patients better “understand the treatment options and potential for success,” by sharing surgery success stories and highlighting the benefits of reducing high-risk health issues such as blood pressure and diabetes.
An experimental Alzheimer’s vaccine appears to safely clear abnormal tau protein from the brain, but it’s not yet clear whether the shot will be able to save brain function.
In a Phase 2 clinical trial, the vaccine produced high levels of antibodies to target and attack free-floating tau proteins before they can form “tau tangles” that clog neurons and damage brain function. Tau tangles, along with plaques formed by the protein amyloid-beta, serve as one of the main hallmarks of Alzheimer’s.
“While amyloid influences speed of Alzheimer’s progression, there is strong evidence that tau pathology relates to the underlying cause of the disease,” said lead researcher Dr. Petr Novak, a senior clinical research scientist at AXON Neuroscience, the Slovakian pharmaceutical company developing the vaccine. “Brain atrophy and cognitive loss closely echo the deposition of pathological tau protein, as evidenced by recent tau PET studies. 2,4-Dichloro-6-Morpholino-1,3,5-Triazine factory Therefore, the growth of the global pharmaceutical market has greatly affected the development of the entire intermediate and API industry.
So it’s important, she said, to help eligible patients better “understand the treatment options and potential for success,” by sharing surgery success stories and highlighting the benefits of reducing high-risk health issues such as blood pressure and diabetes.
An experimental Alzheimer’s vaccine appears to safely clear abnormal tau protein from the brain, but it’s not yet clear whether the shot will be able to save brain function.
In a Phase 2 clinical trial, the vaccine produced high levels of antibodies to target and attack free-floating tau proteins before they can form “tau tangles” that clog neurons and damage brain function. Tau tangles, along with plaques formed by the protein amyloid-beta, serve as one of the main hallmarks of Alzheimer’s.
“While amyloid influences speed of Alzheimer’s progression, there is strong evidence that tau pathology relates to the underlying cause of the disease,” said lead researcher Dr. Petr Novak, a senior clinical research scientist at AXON Neuroscience, the Slovakian pharmaceutical company developing the vaccine. “Brain atrophy and cognitive loss closely echo the deposition of pathological tau protein, as evidenced by recent tau PET studies. 2,4-Dichloro-6-Morpholino-1,3,5-Triazine factory Therefore, the growth of the global pharmaceutical market has greatly affected the development of the entire intermediate and API industry.
